Review Article

Impressive journey of TAVI so far, but miles to go

Rikin Shah*, Bhargav Dave

Research Scientists, Divine CSRD, LLC, 2804 Field Hollow Dr, Pearland TX USA-77584

Received: 08 March 2018
Revised: 02 May 2018
Accepted: 05 May 2018

*Correspondence:
Dr. Rikin Shah,
E-mail: divine.csrd@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Valve replacement is mandatory for AS patients owing to its progressive nature leading to continuous valve degeneration. However, surgical replacement cannot be opted for majority of patients due to old age and affiliated co-morbidities. Over the recent years, AS treatment in high-risk patient population favors a newer, less-invasive method of transcatheter aortic valve implantation (TAVI). The main objective of this review is to revisit all the relevant aspects of TAVI to treat AS in high-risk patients and to assess its possibility as a first-line treatment approach even for low-risk AS patients. We searched PubMed, Google Scholar, Medline and ClinicalTrials.gov to identify all the relevant randomized controlled trials (RCTs) assessing the outcomes of TAVI vs. surgical mode of valve replacement. This method is found to be very safe and reproducible in many landmark clinical trials involving high-risk patients, demonstrating superior or, at least, comparable outcomes vs. surgical mode of treatment. This led to a trend of testing TAVI in lower-risk patient population as well to expand its treatment indication profile.

Keywords: Aortic stenosis, Generation heart valve, Surgical aortic valve replacement (SAVR), Transcatheter aortic valve implantation (TAVI)

INTRODUCTION

Aortic valve degeneration is the most common cause of aortic stenosis (AS). Surgical aortic valve replacement (SAVR) remained a favoured approach to treat severe AS for a prolonged period. However, SAVR was associated with a high operative mortality rate of 7-10% in high-risk groups. Moreover, 30-40% of elderly patients do not opt to go for this surgery. Transcatheter aortic valve implantation (TAVI) was developed to address these unmet needs.1 TAVI revolutionized the treatment of severe AS.2 With more than 100,000 implants performed worldwide, TAVI is stated to change the paradigm in the treatment of AS.3

The feasibility of TAVI was first confirmed in the first decade of 21st century.4 Over the years, a fast-paced development seen in prosthetic valve designing significantly improved procedural success and outcomes of TAVI, with a substantial reduction in complications.5

Isolated AS is reported to be as high as 7.3% in Indians, with the vast majority in geriatric population.6 As per recent Indian demographic data, nearly 3 lac AS patients are estimated to be eligible for TAVI in the near future. Thus, TAVI is stated to become a popular procedure amongst aged Indians as well.2

Pre-TAVI workup in patients and selection for TAVI

The pre-TAVI workup is best achieved in a systematic manner. However, the procedure may not always follow the same line.7

It may be claimed that TAVI is the treatment of choice in inoperable patients, and an effective alternative in high-

ABSTRACT

Valve replacement is mandatory for AS patients owing to its progressive nature leading to continuous valve degeneration. However, surgical replacement cannot be opted for majority of patients due to old age and affiliated co-morbidities. Over the recent years, AS treatment in high-risk patient population favors a newer, less-invasive method of transcatheter aortic valve implantation (TAVI). The main objective of this review is to revisit all the relevant aspects of TAVI to treat AS in high-risk patients and to assess its possibility as a first-line treatment approach even for low-risk AS patients. We searched PubMed, Google Scholar, Medline and ClinicalTrials.gov to identify all the relevant randomized controlled trials (RCTs) assessing the outcomes of TAVI vs. surgical mode of valve replacement. This method is found to be very safe and reproducible in many landmark clinical trials involving high-risk patients, demonstrating superior or, at least, comparable outcomes vs. surgical mode of treatment. This led to a trend of testing TAVI in lower-risk patient population as well to expand its treatment indication profile.

Keywords: Aortic stenosis, Generation heart valve, Surgical aortic valve replacement (SAVR), Transcatheter aortic valve implantation (TAVI)

INTRODUCTION

Aortic valve degeneration is the most common cause of aortic stenosis (AS). Surgical aortic valve replacement (SAVR) remained a favoured approach to treat severe AS for a prolonged period. However, SAVR was associated with a high operative mortality rate of 7-10% in high-risk groups. Moreover, 30-40% of elderly patients do not opt to go for this surgery. Transcatheter aortic valve implantation (TAVI) was developed to address these unmet needs.1 TAVI revolutionized the treatment of severe AS.2 With more than 100,000 implants performed worldwide, TAVI is stated to change the paradigm in the treatment of AS.3

The feasibility of TAVI was first confirmed in the first decade of 21st century.4 Over the years, a fast-paced development seen in prosthetic valve designing significantly improved procedural success and outcomes of TAVI, with a substantial reduction in complications.5

Isolated AS is reported to be as high as 7.3% in Indians, with the vast majority in geriatric population.6 As per recent Indian demographic data, nearly 3 lac AS patients are estimated to be eligible for TAVI in the near future. Thus, TAVI is stated to become a popular procedure amongst aged Indians as well.2

Pre-TAVI workup in patients and selection for TAVI

The pre-TAVI workup is best achieved in a systematic manner. However, the procedure may not always follow the same line.7

It may be claimed that TAVI is the treatment of choice in inoperable patients, and an effective alternative in high-
risk patients considering the outcomes of recent randomized controlled trials. However, over the last few years, there appears to be a trend to favor the treatment of even lower risk patients with TAVI.

Patient evaluation before TAVI should be conducted by a multidisciplinary team. Current guideline recommendations for TAVI patient selection in AS have been explained below in Figure 1.

Table 1: Pre-TAVI evaluations.

| Key evaluations                  | As needed evaluations/additional details                                                                 |
|----------------------------------|----------------------------------------------------------------------------------------------------------|
| **Initial Assessment**           |                                                                                                            |
| AS symptoms and severity         |                                                                                                            |
| Symptoms                         | Intensity, Acuity                                                                                          |
| AS severity                      | Echocardiography and other imaging                                                                       |
| **Baseline clinical data**       |                                                                                                            |
| Cardiac History                  | Prior cardiac interventions                                                                               |
| Physical examination and labs    | Routine blood tests, PFTs                                                                                  |
| Chest Irradiation                | Access issues, other cardiac effects                                                                      |
| Dental Evaluation                | Treat dental issues before TAVI                                                                           |
| Allergies                        | Contrast, latex, medications                                                                               |
| Social Support                   | Recovery, transportation, post-discharge planning                                                         |
| **Major CV co-morbidity**        |                                                                                                            |
| Coronary artery disease          | Coronary angiography                                                                                      |
| LV systolic dysfunction          | LV ejection fraction                                                                                      |
| Concurrent valve disease         | Severe MR or MS                                                                                           |
| Pulmonary hypertension           | Assess pulmonary pressures                                                                                |
| Aortic disease                   | Porcelain aorta (CT scan)                                                                                 |
| Periphera lvascular disease      | Prohibitive re-entry after previous open heart surgery (CT scan), Hostile chest, Imaging for PVD          |
| **Major non-CV comorbidity**     |                                                                                                            |
| Malignancy                       | Remote or active, life expectancy                                                                        |
| Gastrointestinal and liver disease, Bleeding | IBD, cirrhosis, varices, GIB-ability to take anti-platelets/anticoagulation | |
| Kidney disease                   | eGFR <30 cc/min/1.73m² or dialysis                                                                         |
| Pulmonary disease                | Oxygen requirement, FEV₁ <50% predicted or DLCO <50% predicted                                             |
| Neurological disorders           | Movement disorders, dementia                                                                              |
| **Functional Assessment**        |                                                                                                            |
| Frailty and disability           |                                                                                                            |
| Frailty assessment               | Gait speed (<0.5 m/s or <0.83 m/s with disability/cognitive impairment), Fraility (Not frail or frail by assessments) |
| Nutritional risk/status          | Nutritional risk status (BMI <21 kg/m2, albumin <3.5 mg/dl, >10-lb weight loss in past year, or ≤11 on MNA) |
| **Physical function**            |                                                                                                            |
| Physical function and endurance  | 6-min walk <50 m or unable to walk                                                                       |
| Independent living               | Dependent in ≥1 activities                                                                                |
| **Cognitive function**           |                                                                                                            |
| Cognitive impairment             | MMSE <24 or dementia                                                                                      |
| Depression                       | Depression history or positive screen                                                                     |
| Prior disabling stroke           |                                                                                                            |
| **Futility**                     |                                                                                                            |
| Life expectancy                  | <1 year life expectancy                                                                                  |
| Lag-time to benefit              | Survival with benefit of <25% at 2 years                                                                  |

**Patient selection for TAVI as per risk scores**

The decision for SAVR or TAVI in AS also rely on the calculation of risk scores for cardiac surgery (including SAVR): the STS-PROM and the EuroSCORE model. When the STS-PROM score exceeds 10% or when the logistic EuroSCORE is ≥20%, referral for TAVI should be considered. However, some patients as listed in Table 2 have been contraindicated to TAVI procedure as per the established clinical evaluation regime.
Figure 1: Choice of TAVR vs. surgical AVR in the patient with severe symptomatic AS.

Table 2: Contraindications for transcatheter aortic valve implantation.

| Type of contraindications | Particulars |
|---------------------------|-------------|
| **Absolute Contraindications** | Absence of heart team or surgery |
| | Appropriateness of TAVI not confirmed by a “Heart Team” |
| | Estimated life expectancy <1 year. |
| | Unlikely improved quality of life by TAVI. |
| | Severe primary associated disease of other valves. |
| | Inadequate annulus size (<18 mm, >29 mm) |
| | Thrombus in the left ventricle |
| | Active endocarditis |
| | Elevated risk of coronary ostium obstruction |
| | Plaques with mobile thrombi in the ascending aorta, or arch |
| | Inadequate vascular access |
| | Bicuspid or non-calcified valves |
| | Untreated coronary artery disease requiring revascularization |
| | Hemodynamic instability |
| | LVEF < 20% |
| | For transapical approach: severe pulmonary disease, LV apex not accessible |

Note: LVEF, left ventricular ejection fraction

Overview of valve types

**Historical valves**

- The Percutaneous Heart Valve™ comprised a balloon-expandable stainless steel stent initially covering a polyurethane valve.\(^\text{13}\)
- The Paniagua Heart Valve™, consisted a balloon-expandable stent with bovine pericardium valve.\(^\text{14}\)
- The Cribier-Edwards THV™ comprised an equine pericardium valve mounted on a balloon expandable tubular slotted stainless steel stent framework.\(^\text{15}\)

**Commercially available First-Generation transcatheter valves**

**Edwards SAPIEN THV™**

- Bovine pericardium treated to remove calcium-binding sites.
- Updated RetroFlex 1™.
- Shortened nose cone to minimize injury to the left ventricle.
- Available for transapical delivery via the 24Fr Ascendra™ catheter.\(^\text{16}\)

**Medtronic CoreValve™**

- Supra-annular bovine or porcine pericardium valve.
- Self-expanding nickel-titanium alloy frame working on a ’cell’ design.
- Leaflet positioning minimizes disruption of leaflet configuration and co-aptation
- High loop strength and radial force of the central portion.
The stent’s cell structure also facilitates conformation to anatomical discrepancy and functions to minimize coronary ostia obstruction.\textsuperscript{16}

Comparison of Edwards SAPIEN THV\textsuperscript{TM} and Medtronic CoreValve\textsuperscript{TM}

- Found to produce similar clinical outcomes with a few notable exceptions.
- The Medtronic CoreValve\textsuperscript{TM} -
- Significantly higher rates of conduction disturbances and the need for post-procedural PPM.\textsuperscript{17}
- Higher moderate to severe regurgitation and requirement for repeat procedures.\textsuperscript{18}
- Edwards SAPIEN THV\textsuperscript{TM}
- Significantly higher rate of surgical conversion and a higher incidence of major vascular complications.
- Both valves cannot be retrieved or repositioned following deployment.\textsuperscript{17}

Selection of the optimal transcatheter bio-prosthetic valve

Number of modifications have been made to existing devices in attempts to overcome the limitations of earlier-generation valves.\textsuperscript{17}

Table 3: Limitations of first-generation TAVI valves.

| Limitation                                | Associated negative outcomes                          |
|-------------------------------------------|-------------------------------------------------------|
| Inability to reposition, retrieve, or resheath valves | Device embolization or malpositioning                  |
| Paravalvular leak                         | Increased mortality at two-year follow-up             |
| High radial forces associated with aggressive oversizing of the valve prosthesis | Risk of annular rupture                               |
| Subsequent pacemaker requirement          | Atrioventricular conduction abnormality               |
| Placement of large-bore sheaths in femoral arteries | Vascular complications and associated bleeding        |
| Coronary ostial obstruction by the valve and leaflet tissue and embolization | Consequent myocardial infarction                      |
| Embolization of friable material at the time of intervention | Risk of stroke                                       |
| Complex delivery processes                | Multiple operator requirement limiting accuracy of deployment |

Valve can be crimped into a smaller profile.
- 3 sizes - 23 mm, 26 mm and 29 mm.
- The Medtronic CoreValve
- Self-expanding nitinol based valve
- Tri-leaflet porcine pericardial leaflets
- 3 sizes - 26, 29 and 31 mm.\textsuperscript{19}
- Innumerable other valves aiming to be smaller in profile, reduce paravalvular leaks and retrievable.\textsuperscript{19}

Medtronic Evolut\textsuperscript{TM}

- Second-generation CoreValve\textsuperscript{TM} retaining most of the earlier features.
- Reduced overall size
- 10 mm shortening of the outflow tract
- Tailored shape to improve fit and valve retrieval capacity.\textsuperscript{17}

JenaValve\textsuperscript{TM}

- Porcine aortic root valve mounted on a low-profile self-expandable nickel-titanium alloy frame for anterograde transapical implantation.
- It relies on clip fixation of the prosthesis to native aortic valve leaflets to reduce the requirements for high radial forces and larger contact area.\textsuperscript{17}

Sadra Lotus\textsuperscript{TM} (Boston Scientific)

- Repositionable and fully retrievable valve
- Facilitates accurate primary positioning, early valve function, and hemodynamic stability during deployment.
- Minimizes paravalvular regurgitation in patients with severe AS at high or extreme SAVR risk.\textsuperscript{20}

Other investigational devices

A number of new investigational devices have been listed in the following Table 4.

Selection of access route/valve delivery

Transfemoral route

- Current recommendations strongly advocate the femoral route as the preferred TAVI access site.
- Performed under loco-regional anesthesia.
- Following TAVI deployment, anticoagulation state needs to be restored.\textsuperscript{21}

Transapical route

- Purpose-specific Ascendra delivery catheter
- Replaced by the Ascendra 2 system that can accommodate the SAPIEN-XT valve.\textsuperscript{24}
Transaxillary/subclavian route

- Proved particularly advantageous for the CoreValve procedure.
- Initial concerns with the NovaFlex system seem to have been alleviated.\(^{24}\)
- Access to the axillary artery has generally been accomplished in an open fashion, due to the thin friable wall of this artery.\(^{24}\)

Transaortic route

- Generally, been performed with the standard Edwards or Medtronic transarterial delivery system.
- Favorable in patients with compromised arterial access.\(^{24-26}\)

### Table 4: Newer/investigational TAVI devices.

| Valve type | Direct flow medical valve | Heart leaflet technology | Medtronic engager | Edward centera | Edwards Sapien 3 | Colibri heart valve | Boston scientific lotus valve | Aor Tx | Acurate \(\textregistered\) (Symetis) | Portico \(\textregistered\) (St Jude) | Jena Valve\(\textregistered\) |
|------------|--------------------------|--------------------------|-------------------|----------------|-----------------|-------------------|-------------------------------|--------|--------------------------|--------------------------|--------------------------|
| Size (mm)  | 25, 27                   | 21, 23                   | 23, 26            | 23, 26         | 20, 23, 26, 29  | 26                | 23                           | -      | 18, 24 mm                | 23, 25, 27 mm            | -                        |
| Height (mm)| 17 - 18                  | -                        | -                 | 17.5, 20       | 20              | -                 | -                            | -      | -                        | -                        | -                        |
| Leaflet    | Bovine                   | Porcine                  | Bovine            | Bovine         | Bovine (dehyrate) | Bovine           | -                            | Porcine native aortic leaflets | -                        | Porcine                  | Porcine |
| Frame      | Polymer                  | Nickel-titanium alloy    | Nickel-titanium alloy | Cobalt chromium | Nickel-titanium alloy | Nickel-titanium alloy | Nickel-titanium alloy | -      | Porcine Nitinol frame | Nitinol Nitinol          | Nitinol Nitinol |
| Sealing cuff | Polyester               | Polyester               | Polyester          | PET            | PET             | Porcine           | Polyurethane               | 28 Fr  | 18, 24 Fr                 | 32 Fr TA                  | -                       |
| Delivery   | 18Fr, 22Fr (TF)          | 18Fr (TF)                | 29Fr (TA)         | Comman der 14Fr (TA) | 14Fr           | 18Fr             | 24Fr                      | -      | -                        | -                        | -                       |
| Expansion  | Inflation                | Self-expandable         | Self-expandable   | Self-expandable | Balloon-expandaible | Balloon-expandaible | Mechanical | Self-expandable | Self-expandable | Self-expandable |
| Reposition | Yes                      | Yes                      | Yes               | Yes            | No              | No               | Yes                         | Yes    | Yes                      | Yes                      | Yes                      |
| Retrievable | Yes                      | Yes                      | No                | Yes            | No              | No               | Yes                         | Yes    | Yes                      | Yes                      | Yes                      |
| Resheathal | No                       | Yes                      | -                 | Yes            | -               | No               | -                           | Sheathles | -                        | Sheathles                | -                       |
| Trials conducted | Discover | - | Engager™ CE pivotal trial | Feasibility study, 26 mm, 2000-2012, Edwards Center system clinical trial | The partner II trial the sapien 3 study | - | Reprise II | - | Acurate TA® trial | Acurate Neo and TF® trial | First-in-human experience | JUPITE R registry |
| Approved /CE mark | CE mark in 2013 | - | CE mark in 2013 | Under evaluation | CE mark in 2014 | - | CE mark in 2013 | - | CE mark in 2011 | CE mark in 2012 | CE mark, 2012 for AS 2013 for AR |

Reference: \(^{17, 21, 22}\)

International Journal of Research in Medical Sciences | June 2018 | Vol 6 | Issue 6 | Page 1851
TAVI: Published evidence

TAVI in severe senile calcific aortic stenosis: inoperable patients

- In 2010, the first landmark study of TAVI-PARTNER trial B cohort was published.
- 358 symptomatic patients with severe calcific AS not considered for SAVR.
- Randomized to TAVI using the Edwards SAPIEN valve or medical therapy.
- Medically managed non-surgical patients-50% mortality rate in one year.
- All-cause mortality was reduced by an absolute 20% at one year.
- >50% reduction in the incidence of NYHA III or IV symptoms with TAVI.
- Thus, patients who are not candidates for SAVR should be strongly considered for TAVI.

TAVI in severe senile calcific aortic stenosis: surgical candidates

- In 2011, PARTNER A trial results were published.
- 699 symptomatic severe calcific AS patients at high but still acceptable risk for SAVR were randomized to TAVI using SAPIEN valve or SAVR.
- Mortality at 30 days and one year was similar with TAVI and SAVR.
- In 2014, the U.S. CoreValve High Risk Study was published with similar outcomes.
- Primary endpoint of all-cause death in the intention-to-treat analysis was 13.9% vs. 18.7% in the SAVR group (p<0.001 for non-inferiority, p=0.04 for superiority).
- No significant differences between the two groups with respect to functional status and quality of life.
- Strict adjudication of stroke identified no increased risk in the TAVI arm vs. SAVR at 30 days and one year.
- SURTAVI trial
- 1660 patients with a mean age of 79.8 years at intermediate risk for surgery
- TAVI was non-inferior to surgery in patients with severe aortic stenosis at intermediate surgical risk, with a different pattern of adverse events associated with each procedure.

Table 5: Summary of landmark TAVI trials.

| Study                  | Valve used          | Design | Control | No. of TAVI patients | Inclusion criteria                        | Conclusions                                                                 |
|------------------------|---------------------|--------|---------|----------------------|-------------------------------------------|-----------------------------------------------------------------------------|
| PARTNER 1A (2011)      | Edwards SAPIEN      | RCT    | SAVR    | 348                  | Severe AS Symptomatic (NYHA ≥II) high surgical risk | TAVI is non-inferior to AVR in patients with severe AS and high surgical risk. |
| PARTNER 1B (2010)      | Edwards SAPIEN      | RCT    | SMT     | 179                  | high surgical risk                        | TAVI is superior to SMT for patients with severe AS who are unable to undergo AVR. |
| VIVID Registry (2012)  | Edwards SAPIEN      | RCT    | SAVR    | 202 (patients with degenerated bioprosthetic valves) | 1-4 previous SAVR, median time from last SAVR to VIV procedure of 9 years | The valve-in-valve procedure is clinically effective in patients with degenerated bio-prosthetic valves. Safety and efficacy concerns include device malposition, ostial coronary obstruction, and high gradients after the procedure. |
| US CoreValve (2014)    | Medtronic CoreValve| RCT    | SAVR    | 390                  | Severe AS Symptomatic (NYHA ≥II) High surgical risk | TAVI is associated with improved 1-year vs. SAVR for patients with severe AS at high surgical risk. |
| PARTNER 2 (2016)       | Edwards SAPIEN XT   | RCT    | SAVR    | 1011                 | Severe AS Symptomatic (NYHA ≥II) Intermediate surgical risk | TAVI is non-inferior to SAVR in patients with severe AS and intermediate surgical risk. |
| SURTAVI (2017)         | Medtronic CoreValve | RCT    | SAVR    | 864                  |                                            |                                                                            |

TAVI in Severe Bicuspid Aortic Valve Stenosis

- Bicuspid aortic valve (BiAV) degeneration is the most common cause of AS in patients under 65, and accounts for 20% of severe AS cases in octogenarians.
- TAVI has traditionally been considered contraindicated in BiAV stenosis.
- Furthermore, patients with BiAV tend to be younger, leading to concerns about bioprosthesis durability.27

**TAVI in low flow, low gradient severe AS**

- Patients with reduced left ventricular ejection fraction (LVEF) and low flow, low gradient AS have a poor prognosis with medical therapy and a high peri-operative mortality with SAVR.
- Patients with classical LF-LG AS patients had better 2-year survival with TAVI compared to medical therapy. (PARTNER B)
- Two-year survival with TAVI was also similar to SAVR in the randomized PARTNER A trial.
- Better recovery of LVEF has been observed with TAVI vs. SAVR.
- TAVI also provides a therapeutic alternative to SAVR in patients with severe LF-LG AS with preserved LVEF.27,32

**TAVI in severe native aortic valve regurgitation**

TAVI in patients with native aortic valve regurgitation (NAVR) has unique technical challenges related to device anchoring. However, new transcatheter valve designs like JenaValve are addressing these challenges.27

**TAVI for failed aortic bioprostheses**

Concept of a valve-in-valve (ViV), delivered via a catheter, constitutes an attractive alternative. The VIVID registry has recently reported the feasibility and safety of TAVI in 459 patients with a failing aortic bioprosthetic valve.27

**Off-Label indications for TAVI**

- As per the new NCDR STS/ACC TVT Registry, in the US, off-label TAVI is used in approximately 9.5% of patients.
- This registry concluded that approximately 1 in 10 patients in the United States have received TAVI for an off-label indication.
- After adjustment, 1-year mortality was similar in these patients to those receiving TAVI for an on-label indication.33

**Future of TAVI**

**TAVI for patients at lower surgical risk**

- Current strategy revolves around evaluating TAVI for use in patients at lower surgical risk.
- As per a recent propensity score analysis, use of the SAPIEN 3 THV was associated with significantly lower rates of death, stroke, or moderate or severe aortic regurgitation at 1 year of follow-up vs. SAVR.
- These data prompted the FDA to approve the SAPIEN 3 THV for treating patients with severe AS at intermediate surgical risk.34
- Notes of the efficacy of TAVI in patients at low surgical risk were also seen in the NOTION trial.35
- Ongoing RCT such as PARTNER 3, Evolut R Low Risk and NOTION 2 have the capacity to establish TAVI as a first line treatment for AS patients even with low surgical risk.34
- However, the long-term durability of these THVs will determine whether TAVI can be used in younger patients or not.

**Limitations of TAVI to be addressed in the future**

Conduction system disturbances requiring permanent pacemaker implantation after TAVI. However, there has been a dramatic reduction in the rates of stroke and other major vascular complications and a consistent improvement in rates of paravalvular aortic regurgitation.34

**Aortic regurgitation and bicuspid aortic valve disease**

- Though the patient proportion is just 2-6%, bicuspid aortic valve disease is a unique anatomical challenge during TAVI. 34
- In case of a systemic review in aortic regurgitation (AR), including a total of 237 patients with pure native AR from 13 TAVI studies
- CoreValve system were used in 79% of the patients.
- Device success was variable between studies and ranged from 74% to 100%.
- The need for a second valve occurred in up to 7% of patients
- Incidence of moderate-to-severe residual AR was 9%.
- Of note, the stroke rate was extremely low (0%), and 30-day mortality was 7% (3-13%).35

**Imaging issues**

Utility of imaging to improve prediction of TAVI-related outcomes is an emerging issue, particularly for patients with particular characteristics rendering them at greater risk of procedural complications and suboptimal outcomes. Fusion imaging and simulation of device implantation will probably have an increasing role in future TAVI. 34 The future of TAVI seems bright, with upcoming trials expected to increase the safety and efficacy of the procedure, reducing potential making TAVI a viable and a turning point procedure to treat most patients with severe aortic valve disease.

**CONCLUSION**

The establishment of TAVI rudimentarily changed the management of AS. The continuous improvement in existing valve design and the introduction of novel
devices enabled a continued extension of this field. Further, as the results improve, and valve durability is determined, an extended application of this technology to lower-risk patients is also projected.

**Funding: No funding sources**

**Conflict of interest: None declared**

**Ethical approval: The study was approved by the Institutional Ethics Committee**

**REFERENCES**

1. Al-Lamee R, Godino C, Colombo A. Transcatheter aortic valve implantation: Current principles of patient and technique selection and future perspectives. Circ Cardiovasc Interv. 2011;4(4):387-95.

2. Jose J, Manik G, Abdel-Wahab M. Setting up a transcatheter aortic valve implantation program: Indian perspective. Ind Heart J. 2016;68(5):732-6.

3. Thielmann M, Tsagakis K, El Gabry M, Jakob H, Wendt D. Transcatheter aortic valve implantation (TAVI) in patients with aortic regurgitation. Ann Cardiothorac Surg. 2017;6(5):558-60.

4. Rodés-Cabau J. Transcatheter aortic valve implantation: Current and future approaches. Nat Rev Cardiol. 2012;9(1):15-29.

5. Bax JJ, Delgado V, Bapat V, Baumgartner H, Collet JP, Erbel R, et al. Open issues in transcatheter aortic valve replacement. Part 1: Patient selection and treatment strategy for transcatheter aortic valve implantation. Eur Heart J. 2014;35(38):2627-38.

6. Manjunath CN, Srinivas P, Ravindranath KS, Dhanalakshmi C. Incidence and patterns of valvular heart disease in a tertiary care high-volume cardiac center: A single center experience. Indian Heart J. 2014;66(3):320-6.

7. Braxton JH, Rasmussen KS, Shah MS. Transcatheter Aortic Valve Replacement: A Review. Surg Clin North Am. 2017;97(4):899-921.

8. Otto CM, Kumbhani DJ, Alexander KP, Calhoon JH, Desai MY, Kaul S, et al. 2017 ACC expert consensus decision pathway for transcatheter aortic valve replacement in the management of adults with aortic stenosis: a report of the American college of cardiology task force on clinical expert consensus documents. J Am Coll Cardiol. 2017;69(10):1313-46.

9. Bourantas CV, Van Mieghem NM, Faroq V, Soliman OI, Windecker S, Piazza N, et al. Future perspectives in transcatheter aortic valve implantation. Int J Cardiol. 2013;168(1):11-8.

10. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher LA, et al. 2017 AHA/ACC focused update of the 2014 aha/ACC guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2017;70(2):252-89.

11. Cocchia R, D’Andrea A, Conte M, Cavallaro M, Riegler L, Citro R, et al. Patient selection for transcatheter aortic valve replacement: A combined clinical and multimodality imaging approach. World J Cardiol. 2017;9(3):212.

12. Munoz A, Gomez-Doblas JJ. Patient selection for TAVI. E-journal Cardiol Pract. 2016; Available from: http://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-14/patient-selection-for-tavi.

13. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: First human case description. Circulation. 2002;106(24):3006-8.

14. Paniagua D, Condado JA, Besso J, Vélez M, Burger B, Bibbo S, et al. First human case of retrograde transcatheter implantation of an aortic valve prosthesis. Tex Heart Inst J. 2005;32(3):393-8.

15. Webb JG, Chandavimol M, Thompson CR, Ricci DR, Carere RG, Mint B, et al. Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation. 2006;113(6):842-50.

16. Piazza N, de Jaegere P, Schultz C, Becker AE, Serruys PW, Anderson RH. Anatomy of the aortic valvar complex and its implications for transcatheter implantation of the aortic valve. Circ Cardiovasc Interv. 2008;1(1):74-81.

17. Fanning JP, Platts DG, Walters DL, Fraser JF. Transcatheter aortic valve implantation (TAVI): Valve design and evolution. Int J Cardiol. 2013;168(3):1822-31.

18. Kazan R, Cyr S, Hemmerling TM, Lin SJ, Gelardino MS. The Evolution of Surgical Simulation. Plast Reconstr Surg. 2017;139(2):533e-543e.

19. Tay E. Transcatheter aortic valve implantation emerging as good alternative to surgery for aortic stenosis—present status. 2015;3(1):3-7.

20. Meredith IT, Walters DL, Dumontel N, Worthley SG, Tchétché D, Manoharan G, et al. 1-year outcomes with the fully repositionable and retrievable lotus transcatheter aortic replacement valve in 120 high-risk surgical patients with severe aortic stenosis: Results of the REPRISE II study. JACC Cardiovasc Interv. 2016;9(4):376-84.

21. Lefèvre T, Colombo A, Tchétché D, Latib A, Klugmann S, Fajadet J, et al. Prospective multicenter evaluation of the direct flow medical transcatheter aortic valve system 12-month outcomes of the evaluation of the direct flow medical percutaneous aortic valve 18F system for the treatment of patients with severe aortic stenosis. JACC Cardiovasc Interv. 2016;9(1):68-75.

22. Kılıç T, Yılmaz I. Transcatheter aortic valve implantation: a revolution in the therapy of elderly and high-risk patients with severe aortic stenosis. J Geriatr Cardiol. 2017;14(3):204-17.

23. Pascual I, Carro A, Avanza P, Hernández-Vaquero D, Díaz R, Rozado J, et al. Vascular approaches for
transcatheter aortic valve implantation. J Thorac Dis. 2017;9(5):S478-87.
24. Webb IG, Binder RK. Transcatheter aortic valve implantation: The evolution of prostheses, delivery systems and approaches. Arch Cardiovasc Dis. 2012;105(3):153-9.
25. Bapat V, Khawaja MZ, Attia R, Narayana A, Wilson K, Magillivray K, et al. Transaortic transcatheter aortic valve implantation using Edwards SAPIEN valve: A novel approach. Catheter Cardiovasc Interv. 2012;79(5):733-40.
26. Etienne PY, Papadatos S, El Khoury E, Pieters D, Price J, Glineur D. Transaortic transcatheter aortic valve implantation with the Edwards Sapien valve: Feasibility, technical considerations, and clinical advantages. Ann Thorac Surg. 2011;92(2):746-8.
27. Yousef A, Froeschl M, Hibbert B, Burwash IG, Labinaz M. Transcatheter aortic valve implantation: current and evolving indications. Can J Cardiol. 2016;32(2):266-9.
28. Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009;360:859-73.
29. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370(19):1790-8.
30. Yousef A, Simard T, Pourjabbar A, Webb J, So D, Chong AY, et al. Performance of transcatheter aortic valve implantation in patients with bicuspid aortic valve: Systematic review. Int J Cardiol. 2014;176(2):562-4.
31. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Søndergaard L, Muntaz M, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2017;376(14):1321-31.
32. Herrmann HC, Pibarat P, Hueter I, Gertz ZM, Stewart WJ, Kapadia S, et al. Predictors of mortality and outcomes of therapy in low-flow severe aortic stenosis: A placement of aortic transcatheter valves (PARTNER) trial analysis. Circulation. 2013;127(23):2316-26.
33. Hira RS, Vemulapalli S, Li Z, McCabe JM, Rumssfeld JS, Kapadia SR, et al. Trends and outcomes of off-label use of transcatheter aortic valve replacement: Insights from the NCDR STS/ACC TVT registry. JAMA Cardiol. 2017;2(8):846-54.
34. Puri R, Chamandi C, Rodriguez-Gaballa T, Rodés-Cabau J. Future of transcatheter aortic valve implantation-evolving clinical indications. Nat Rev Cardiol. 2018;15(1):57-65.
35. Thryegod HGH, Steinbrüchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol. 2015;65(20):2184-94.
36. Yes Latest DVIR Long Term PCR.
37. Franzone A, Piccolo R, Siotis GCM, Lanz J, Stortecky S, Praz F, et al. Transcatheter aortic valve replacement for the treatment of pure native aortic valve regurgitation: a systematic review. JACC Cardiovasc Interv. 2016;9(22):2308-17.
38. Ali N, Patel PA, Lindsay SJ. Recent developments and controversies in transcatheter aortic valve implantation. Eur J Heart Fail. 2018;1-9.
39. Dvir D, Webb J, Brecker S, Bleiziffer S, Hildick-Smith D, Colombo A, et al. Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: Results from the global valve-in-valve registry. Circulation. 2012;126(19):2335-44.

Cite this article as: Shah R, Dave B. Impressive journey of TAVI so far, but miles to go. Int J Res Med Sci 2018;6:1847-55.